Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
BMJ Open|April 18, 2023
Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare systemLarry Alphs, Ibrahim Turkoz, Virginia Smith-Swintosky, et al.
Journal of Clinical Psychopharmacology|December 27, 2011
Asenapine versus olanzapine in people with persistent negative symptoms of schizophreniaRobert W Buchanan, John Panagides, Jun Zhao, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Pharmacogenetics and Genomics|February 26, 2015
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophreniaDai Wang, Dong-Jing Fu, Xiaodong Wu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Suicidal ideation and behavior assessment in dementia studies: An Internet surveyPhillip Chappell, Sarah Dubrava, Michelle Stewart, et al.
Neuroscience Applied|June 8, 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurementArmida Mucci, Michael Davidson, Silvia Zaragoza Domingo, et al.
The Journal of Clinical Psychiatry|July 7, 2017
Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus MeetingPhillip B Chappell, Michelle Stewart, Larry Alphs, et al.
Schizophrenia Bulletin|January 6, 2005
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patientsLarry Alphs, Ravi Anand, M Zahur Islam, et al.
Innovations in Clinical Neuroscience|February 21, 2012
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scaleMichael H Allen, David G Daniel, Dennis A Revicki, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
BMJ Open|April 18, 2023
Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare systemLarry Alphs, Ibrahim Turkoz, Virginia Smith-Swintosky, et al.
Journal of Clinical Psychopharmacology|December 27, 2011
Asenapine versus olanzapine in people with persistent negative symptoms of schizophreniaRobert W Buchanan, John Panagides, Jun Zhao, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Pharmacogenetics and Genomics|February 26, 2015
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophreniaDai Wang, Dong-Jing Fu, Xiaodong Wu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Suicidal ideation and behavior assessment in dementia studies: An Internet surveyPhillip Chappell, Sarah Dubrava, Michelle Stewart, et al.
Neuroscience Applied|June 8, 2026
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurementArmida Mucci, Michael Davidson, Silvia Zaragoza Domingo, et al.
The Journal of Clinical Psychiatry|July 7, 2017
Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus MeetingPhillip B Chappell, Michelle Stewart, Larry Alphs, et al.
Schizophrenia Bulletin|January 6, 2005
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patientsLarry Alphs, Ravi Anand, M Zahur Islam, et al.
Innovations in Clinical Neuroscience|February 21, 2012
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scaleMichael H Allen, David G Daniel, Dennis A Revicki, et al.
Pageof 12